Patient-derived xenograft models positive for ERG overexpression treated with YK-4-279 showed a heterogeneous response, with a significant decrease in cell proliferation and tumor volume and prostate-specific antigen (PSA) decline in one line and only partial response in another on three xenografts tested [147]. This evidence concerns the gene ERG and neoplasm.